[go: up one dir, main page]

WO2003030867A3 - Procede de preparation d'un compose d'interaction d'un derive anilide avec un support poreux par fluide supercritique - Google Patents

Procede de preparation d'un compose d'interaction d'un derive anilide avec un support poreux par fluide supercritique Download PDF

Info

Publication number
WO2003030867A3
WO2003030867A3 PCT/FR2002/003475 FR0203475W WO03030867A3 WO 2003030867 A3 WO2003030867 A3 WO 2003030867A3 FR 0203475 W FR0203475 W FR 0203475W WO 03030867 A3 WO03030867 A3 WO 03030867A3
Authority
WO
WIPO (PCT)
Prior art keywords
supercritical fluid
porous support
anilide derivative
preparing
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2002/003475
Other languages
English (en)
Other versions
WO2003030867A2 (fr
Inventor
Bernard Freiss
Florence Marciacq
Jacques Fages
Martial Sauceau
Hubert Lochard
Jean-Jacques Letourneau
Christophe Joussot-Dubien
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Original Assignee
Pierre Fabre Medicament SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pierre Fabre Medicament SA filed Critical Pierre Fabre Medicament SA
Priority to AU2002360112A priority Critical patent/AU2002360112A1/en
Publication of WO2003030867A2 publication Critical patent/WO2003030867A2/fr
Publication of WO2003030867A3 publication Critical patent/WO2003030867A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

La présente invention a pour objet un procédé de préparation de composés d'interaction du dérivé d'anilide avec un support poreux, caractérisé en ce qu'il comprend les étapes suivantes: (a) mélanger le dérivé d'anilide généré par fluide supercritique et la quantité déterminée de support poreux, (b) mettre en oeuvre une étape de diffusion moléculaire par mise en contact en mode statique d'un fluide supercritique avec le mélange obtenu à l'étape (a) pendant le temps nécessaire pour améliorer la dissolution dans un milieu aqueux du mélange obtenu à l'étape (a), (c) laver le composé d'interaction obtenue à l'étape (b) par un flux de fluide supercritique, (d) récupérer les particules du composé d'interaction ainsi formé. Elle concerne également un composé susceptible d'être obtenu par ce procédé et son utilisation en tant que médicament
PCT/FR2002/003475 2001-10-12 2002-10-11 Procede de preparation d'un compose d'interaction d'un derive anilide avec un support poreux par fluide supercritique Ceased WO2003030867A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002360112A AU2002360112A1 (en) 2001-10-12 2002-10-11 Method for preparing an interactive compound of an anilide derivative with a porous support by supercritical fluid

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR01/13179 2001-10-12
FR0113179A FR2830761B1 (fr) 2001-10-12 2001-10-12 Procede de preparation d'un compose d'interaction d'un derive anilide avec un support poreux par fluide supercritique

Publications (2)

Publication Number Publication Date
WO2003030867A2 WO2003030867A2 (fr) 2003-04-17
WO2003030867A3 true WO2003030867A3 (fr) 2003-12-04

Family

ID=8868229

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2002/003475 Ceased WO2003030867A2 (fr) 2001-10-12 2002-10-11 Procede de preparation d'un compose d'interaction d'un derive anilide avec un support poreux par fluide supercritique

Country Status (3)

Country Link
AU (1) AU2002360112A1 (fr)
FR (1) FR2830761B1 (fr)
WO (1) WO2003030867A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2854079B1 (fr) * 2003-04-25 2007-11-30 Pf Medicament Procede de preparation de complexes moleculaires
FR2876911B1 (fr) * 2004-10-21 2007-04-13 Pierre Fabre Medicament Sa Complexe comprenant du piroxicam, une cyclodextrine et de l'arginine
JP5091661B2 (ja) 2004-04-01 2012-12-05 ピエール ファーブル メディカモン 超臨界ｃｏ２と錯体相互作用剤を用いる方法によって得られる包接錯体
FR2876910B1 (fr) 2004-10-21 2007-04-13 Pierre Fabre Medicament Sa Complexe comprenant la mequitazine, une cyclodextrine et un agent d'interaction

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997019918A1 (fr) * 1995-11-28 1997-06-05 Pierre Fabre Medicament Nouveaux derives de 2,3,5 trimethyl-4-hydroxy anilides, leur preparation et leur application en therapeutique
WO2001043853A1 (fr) * 1999-12-15 2001-06-21 SEPAREX (Société Anonyme) Procede et dispositif de captage de fines particules par percolation dans un lit de granules

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997019918A1 (fr) * 1995-11-28 1997-06-05 Pierre Fabre Medicament Nouveaux derives de 2,3,5 trimethyl-4-hydroxy anilides, leur preparation et leur application en therapeutique
WO2001043853A1 (fr) * 1999-12-15 2001-06-21 SEPAREX (Société Anonyme) Procede et dispositif de captage de fines particules par percolation dans un lit de granules

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FABIEN MILLIAT; ET AL.: "Overexpression of SR-BI in hamsters treated with a novel ACAT inhibitor (F12511)", COMPTES RENDUS DES SEANCES DE L'ACADEMIE DES SCIENCES. SERIE III: SCIENCES DE LA VIE, vol. 324, no. 3, March 2001 (2001-03-01), Amsterdam (NL), pages 229 - 234, XP004270528 *
T. VAN HEES ET AL.: "Application of supercritical carbon dioxide for the preparation of a piroxicam-beta-cyclodextrin inclusion compound", PHARMACEUTICAL RESEARCH, vol. 16, no. 12, 1999, New York (US), pages 1864 - 1870, XP002240406 *

Also Published As

Publication number Publication date
WO2003030867A2 (fr) 2003-04-17
FR2830761A1 (fr) 2003-04-18
FR2830761B1 (fr) 2003-12-12
AU2002360112A1 (en) 2003-04-22

Similar Documents

Publication Publication Date Title
CY1107306T1 (el) Μεθοδος παρασκευης μιας ενωσεως αλληλεπιδρασεως δραστικων ουσιων με ενα πορωδες υποστρωμα μεσω ενος υπερκρισιμου ρευστου
WO2004103539A3 (fr) Procede pour former une emulsion par la technique de traitement en microcanal
Katayama et al. Highly Selective Ring-Opening/Cross-Metathesis Reactions of Norbornene Derivatives Using Selenocarbene Complexes as Catalysts This work was supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Science, Sports, and Culture, Japan
WO2002060578A1 (fr) Dispositif servant a activer une substance au moyen d'une structure active et dispositif servant a generer un gaz
DE60200412D1 (de) Polyhydroxyalkanoat und Verfahren zu dessen Herstellung, und Omega-(2-Thienylsulfanyl)alkansäure und Verfahren zu deren Herstellung
EP2266684A3 (fr) Procédé pour la formation d'une émulsion utilisant la technologie de procédé de microcanaux
ATE484753T1 (de) Hämatologie-blutkontrolle und verfahren zu ihrer herstellung
DE60217203D1 (de) Poröse Teilchen, wässrige Dispersionen und Verfahren zu ihrer Herstellung
ES1063053Y (es) Dispositivo para producir microespuma
AU2002212412A1 (en) Method for making very fine particles consisting of a principle inserted in a host molecule
DK0967176T3 (da) Agglomerater på basis af aktivt kul, deres fremstillingsmåde og anvendelse som adsorptionsmidler
WO2005035142A3 (fr) Applicateur de produit liquide
MXPA03005492A (es) Metodo para la concentracion de acido gastado.
WO2003030867A3 (fr) Procede de preparation d'un compose d'interaction d'un derive anilide avec un support poreux par fluide supercritique
EP1331032A3 (fr) Procédé d'immobilisation d'un catalyseur homogène, et materiau catalytique
NO20055467L (no) Fremgangsmate til fremstilling av molekylaere komplekser
BR9902639B1 (pt) processo para preparação de acetato de vinila bruto, lìquido.
WO2005097201A3 (fr) Complexes d’inclusions comprenant du piroxicam, une cyclodextrine et l’arginine
DK32297A (da) Fremgangsmåde til fremstillingen af et mellemprodukt, som kan anvendes ved syntesen af ioderede kontrastmedier
ATE368451T1 (de) Verfahren zum überziehen von feststoffteilchen
JP2002275230A5 (fr)
ATE374177T1 (de) Cyclohexyl(alkyl)-propanolamine, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen
WO2004063095A3 (fr) Procede de production de solvant permettant d'obtenir une solubilite elevee du calcium, poudre de calcium presentant une solubilite elevee et liquide a base de calcium ainsi obtenu
JP2006512188A5 (fr)
UA69968A (en) A method for a complex treatment of bottomhole zone of gas and gas-condensate boreholes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU BR CA CN JP MX US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FR GB GR IE IT LU MC NL PT SE SK TR US

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP